Get started
PROCEPT BioRobotics CorporationPROCEPT BioRobotics CorporationPROCEPT BioRobotics Corporation

PROCEPT BioRobotics Corporation

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

PRCT chart


Full chart

PRCT upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪4.46 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.95 USD
Net income (FY)
‪−105.90 M‬ USD
Revenue (FY)
‪136.19 M‬ USD
Shares float
‪51.55 M‬
Beta (1Y)
1.28

Employees


Employees (FY)
626
Change (1Y)
+198 +46.26%
Revenue / Employee (1Y)
‪217.56 K‬ USD
Net income / Employee (1Y)
‪−169.16 K‬ USD

About PROCEPT BioRobotics Corporation


Sector
Health Technology
Industry
Medical Specialties
CEO
Reza Zadno
Website
procept-biorobotics.com
Headquarters
San Jose
Founded
2007
FIGI
BBG009KD84H4
PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. It manufactures and sells the AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating BPH. The firm's proprietary AquaBeam Robotic System employs a single-use disposable handpiece to deliver its Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. The company was founded by Nikolai Aljuri and Rodney C. Perkins in 2007 and is headquartered in San Jose, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

PRCT news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of PRCT is 79.89 USD — it has decreased by −2.58% in the past 24 hours. Watch PROCEPT BioRobotics Corporation stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange PROCEPT BioRobotics Corporation stocks are traded under the ticker PRCT.
PRCT stock has fallen by −1.54% compared to the previous week, the month change is a −17.86% fall, over the last year PROCEPT BioRobotics Corporation has showed a 85.93% increase.
We've gathered analysts' opinions on PROCEPT BioRobotics Corporation future price: according to them, PRCT price has a max estimate of 115.00 USD and a min estimate of 95.00 USD. Watch PRCT chart and read a more detailed PROCEPT BioRobotics Corporation stock forecast: see what analysts think of PROCEPT BioRobotics Corporation and suggest that you do with its stocks.
PRCT reached its all-time high on Nov 11, 2024 with the price of 103.81 USD, and its all-time low was 15.38 USD and was reached on Jan 24, 2022. View more price dynamics on PRCT chart.
See other stocks reaching their highest and lowest prices.
PRCT stock is 3.08% volatile and has beta coefficient of 1.28. Track PROCEPT BioRobotics Corporation stock price on the chart and check out the list of the most volatile stocks — is PROCEPT BioRobotics Corporation there?
Today PROCEPT BioRobotics Corporation has the market capitalization of ‪4.46 B‬, it has increased by 1.92% over the last week.
Yes, you can track PROCEPT BioRobotics Corporation financials in yearly and quarterly reports right on TradingView.
PROCEPT BioRobotics Corporation is going to release the next earnings report on Mar 4, 2025. Keep track of upcoming events with our Earnings Calendar.
PRCT earnings for the last quarter are −0.40 USD per share, whereas the estimation was −0.49 USD resulting in a 18.13% surprise. The estimated earnings for the next quarter are −0.34 USD per share. See more details about PROCEPT BioRobotics Corporation earnings.
PROCEPT BioRobotics Corporation revenue for the last quarter amounts to ‪58.37 M‬ USD, despite the estimated figure of ‪53.30 M‬ USD. In the next quarter, revenue is expected to reach ‪66.83 M‬ USD.
PRCT net income for the last quarter is ‪−20.97 M‬ USD, while the quarter before that showed ‪−25.63 M‬ USD of net income which accounts for 18.15% change. Track more PROCEPT BioRobotics Corporation financial stats to get the full picture.
No, PRCT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 30, 2024, the company has 626.00 employees. See our rating of the largest employees — is PROCEPT BioRobotics Corporation on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. PROCEPT BioRobotics Corporation EBITDA is ‪−101.36 M‬ USD, and current EBITDA margin is −77.36%. See more stats in PROCEPT BioRobotics Corporation financial statements.
Like other stocks, PRCT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade PROCEPT BioRobotics Corporation stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So PROCEPT BioRobotics Corporation technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating PROCEPT BioRobotics Corporation stock shows the buy signal. See more of PROCEPT BioRobotics Corporation technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.